Here we describe a novel, potent non-steroidal ER antagonist and degrader, GDC-0810, that is orally bioavailable and has strong anti-tumor activity in endocrine-sensitive and -resistant models of ER+ breast cancer. Here, ESR1 is linked to breast carcinoma.